Primary Blasts from Infants with Acute Lymphoblastic Leukemia Cause Overt Leukemia in SOD Mice

Leukemia and Lymphoma

Volumn 30, Issue 42067, 1998, Pages 269-277

  Uckun, Fatih M ^a   Waurzyniak, Barbara J ^a   Sensel, Martha G ^a   Chelstrom, Lisa ^a   Crotty, Mya Lisa ^a   Gaynon, Paul S ^b   Reaman, Gregory H ^c,d  

^a Department of Genetics   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

acute lymphoblastic leukemia; Blasts; infant ALL; leukemia in mice; SCID mice

Indexed keywords

ANTIINFECTIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 7; CHROMOSOME TRANSLOCATION 9; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFANT; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFANT; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROGNOSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 0031847120     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199809057540     Document Type: Article

References (51)

1. Pui C.H., Kane J.R., Crist W.M. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762 – 9
2. Uckun F., Reaman G., Steinherz P., Arthur D., Sather H., Trigg M., Tubergen D., Gaynon P. Improved outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group study. Leuk Lymphoma 1996; 24: 57 – 70
3. Tubergen D., Gilchrist G., O'Brien R., Coccia P., Sather H., Waskerwitz M., Hammond D. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1993; 11: 527 – 537
4. Steinherz P.G., Gaynon P., Miller D.R., Reaman G., Bleyer A., Finklestein J., Evans R.G., Meyers P., Steinherz L.J., Sather H., Hammond D. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen-a new intensive therapy protocol: a report from the Children's Cancer Study Group. J Clin Oncol 1986; 4: 744 – 52
5. Reaman G., Zeltzcr P., Bleyer W.A., Amendola B., Level C., Sather H., Hammond D. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3: 1513 – 21
6. Reaman G.H., Steinherz P.G., Gaynon P.S., Bleyer W.A., Finklestein J.Z., Evans R., Miller D.R., Sather H.N., Hammond G.D. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987; 71: 1033 – 8
7. Pui C.H., Ribeiro R.C., Campana D., Raimondi S.C., Hancock M.L., Behm F.G., Sandlund J.T., Rivera G.K., Evans W.E., Crist W.M., Krance R. Prognostic factors in the acute lymphoid and myeloid leukemiasof infants. Leukemia 1996; 10: 952 – 6
8. Cimino G., Rapanotti M.C., Rivolta A., Lo Coco F. E. D. A., Rondelli R., Basso G., Barisone E., Rosanda C., Santostasi T., et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995; 9: 391 – 5
9. Basso G., Rondelli R., Covezzoli A., Putti M. The role of immunophenotype in acute lymphoblastic leukemia of infant age. Leuk Lymphoma 1994; 15: 51 – 60
10. Barry T.S., Jones D.M., Richter C.B., Haynes B.F. Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens. J Exp Med 1991; 173: 167 – 80
11. Cesano A. R. O. C., Lange B., Finan J., Rovera G., Santoli D. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 1991; 11: 2463 – 74
12. Dick J.E., Lapidot T., Pflumio F. Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev 1991; 124: 25 – 43
13. Kamel Reid S., Letarte M., Sirard C., Docdens M., Grunberger T., Fulop G., Freedman M.H., Phillips R.A., Dick J.E. A model of human acute lymphoblastic leukemia in immune-deficient scid mice. Science 1989; 246: 1597 – 600
14. Kamel Reid S., Letarte M., Doedens M., Greaves A., Murdoch B., Grunberger T., Lapidot T., Thorner P., Freedman M.H., Phillips R.A., et al. Bone marrow from children in relapse with Pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood 1991; 78: 2973 – 81
15. McCune J.M., Namikawa R., Kaneshima H., Shultz L.D., Lieberman M., Weissman I.L. The SClD-hu mouse: murine model for the analysis of human hematolym-phoid differentiation and function. Science 1988; 241: 1632 – 9
16. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256 – 9
17. Uckun F.M., Downing J.R., Gunther R., Chelstrom L.M., Finnegan D., Land V.J., Borowitz M.J., Carroll A.J., Crist W.M. Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1993; 81: 3052 – 62
18. Uckun F.M., Manivel C., Arthur D., Chelstrom L.M., Finnegan D., Tuel Ahlgren L., Irvin J.D., Myers D.E., Gunther R. In vivo efficacy of B43 (anti-CD 19)-poke-weed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201 – 14
19. Uckun F.M., Downing J.R., Chelstrom L.M., Gunther R., Ryan M., Simon J., Carroll A.J., Tuel Ahlgren L., Crist W.M. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1994; 84: 859 – 65
20. Uckun F.M., Sather H., Reaman G., Shuster J., Land V., Trigg M., Gunther R., Chelstrom L., Bleyer A., Gaynon P., et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995; 85: 873 – 8
21. Bostrom B., Erdmann G.E., Kamen B.A. Intrathecal (IT) methotrexate (MTX) results in greater systemic exposure than oral as evidenced by red cell methotrexate concentrations (Meeting abstract). J Clin Oncol 1996; 15
22. Nachman J., Sather H.N., Gaynon P.S., Lukens J.N., Wolff L., Trigg M.E. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 2222 – 2230
23. Nachman J., Sather H., Lukens S., Gaynon P., Wolff L., Arthur D., Cherlow J., Trigg M. Cranial radiation (CRT) improves event free survival (EFS) forhigh risk patients with acute lymphoblastic leukemia (ALL) showing a rapid response (RR) to BFM induction chemotherapy (Meeting abstract). Proc Amer Soc Clin Oncol 1994; 13, Abstract #1042
24. Uckun F.M., Ledbetter J.A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci U S A 1988; 85: 8603 – 7
25. Uckun F.M., Muraguchi A., Ledbetter J.A., Kishimoto T., Rt O.B., Roloff J.S., Gajl Peczalska K., Provisor A., Koller B. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989; 73: 1000 – 15
26. Heerema N.A., Palmer C.G., Baehner R.L. Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. Cancer Genet Cytogenet 1985; 17: 165 – 79
27. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Karger, Basel Switzerland 1995
28. Downing J.R., Head D.R., Raimondi S.C., Carroll A.J., Curcio Brint A.M., Motroni T.A., Hulshof M.G., Pullen D.J., Domer P.H. The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 1994; 83: 330 – 5
29. Gaynon P.S., Crotty M.L., Sather H.N., Bostrom B.C., Nachman J.B., Steinherz P.G., Heerema N.A., Sarquis M., Tuel-Ahlgren L., Uckun F.M. Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. Leuk Lymphoma 1997; 26: 57 – 65
30. Gunther R., Chelstrom L.M., Finnegan D., Tuel Ahlgren L., Irvin J.D., Myers D.E., Uckun F.M. In vivo anti-leukemic efficacy of anti-CD7-pokcweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993; 7: 298 – 309
31. Uckun F.M. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908 – 23
32. Pui C.H., Raimondi S.C., Murphy S.B., Ribeiro R.C., Kalwinsky D.K., Dahl G.V., Crist W.M., Williams D.L. An analysis of leukemic cell chromosomal features in infants. Blood 1987; 69: 1289 – 93
33. Pui C.H., Behm F.G., Downing J.R., Hancock M.L., Shurtleff S.A., Ribeiro R.C., Head D.R., Mahmoud H.H., Sandlund J.T., Furman W.L., et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909 – 15
34. Taki T., Ida K., Bessho F., Hanada R., Kikuchi A., Yamamoto K., Sako M., Tsuchida M., Seto M., Ueda R., Hayashi Y. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996; 10: 1303 – 7
35. Hilden J.M., Frestedt J.L., Moore R.O., Heerema N.A., Arthur D.C., Reaman G.H., Kersey J.H. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 1995; 86: 3876 – 82
36. Hilden J.M., Kersey J.H. The MLL (11q23) and AF-4 (4q21) genes disrupted in t(4;11) acute leukemia: molecular and clinical studies. Leuk Lymphoma 1994; 14: 189 – 95
37. Heerema N.A., Arthur D.C., Sather H., Albo V., Feusner J., Lange B.J., Steinherz P.G., Zeltzer P., Hammond D., Reaman G.H. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children's Cancer Group. Blood 1994; 83: 2274 – 84
38. Behm F.G., Raimondi S.C., Frestedt J.L., Liu Q., Crist W.M., Downing J.R., Rivera G.K., Kersey J.H., Pui C.H. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870 – 7
39. Ludwig W.D., Bartram C.R., Harbott J., Koller U., Haas O.A., Hansen Hagge T., Heil G., Seibt Jung H., Teichmann J.V., Ritter J., et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia 1989; 3: 431 – 9
40. Ishii E., Okamura J., Tsuchida M., Kobayashi M., Akiyama Y., Nakahata T., Kojima S., Hanada R., Horibe K., Sato T., et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 1991; 19: 28 – 32
41. Basso G., Putti M.C., Cantu Rajnoldi A., Saitta M., Santostasi T., Santoro N., Lippi A., Comelli A., Felici L., Favre C., et al. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. an Italian multicentre study (Aieop). Br J Haematol 1992; 81: 184 – 91
42. Cantu Rajnoldi A., Putti C., Saitta M., Granchi D., Foa R., Schiro R., Castagni M., Valeggio C., Jankovic M., Miniero R., et al. Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: relationship with the stage of differentiation and clinical significance [see comments]. Br J Haematol 1991; 79: 40 – 3
43. Bucsky P., Reiter A., Ritter J., Dopfer R., Riehm H. [Acute lymphoblastic leukemia in infancy: results of 5 multicenter All-Bfm therapy studies 1970-1986]. Klin Padiatr 1988; 200: 177 – 83
44. Chen C.S., Sorensen P.H., Domer P.H., Reaman G.H., Korsmeyer S.J., Heerema N.A., Hammond G.D., Kersey J.H. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386 – 93
45. Chessells J.M., Eden O.B., Bailey C.C., Lilleyman J.S., Richards S.M. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8: 1275 – 9
46. Ferster A., Bertrand Y., Benoit Y., Boilletot A., Behar C., Margueritte G., Thyss A., Robert A., Mazingue F., Souillet G., et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994; 86: 284 – 90
47. Schorin M.A., Blattner S., Gelber R.D., Tarbell N.J., Donnelly M., Dalton V., Cohen H.J., Sallan S.E. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994; 12: 740 – 7
48. Waddick K.G., Myers D.E., Gunther R., Chelstrom L.M., Chandan Langlie M., Irvin J.D., Turner N., Uckun F.M. In vitro, in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood 1995; 86: 4228 – 33
49. Waurzyniak B., Schneider E.A., Turner N., Yanishevski Y., Gunther R., Chelstrom L.M., Wendorf H., Myers D.E., Irvin J.D., Messinger Y., Onur E., Zeren T., Langlie M.C., Evans W.E., Uckun F.M. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (Anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997; 3: 881 – 890
50. Uckun F.M., Stewart C.F., Reaman G., Chelstrom L.M., Jin J., Chandan Langlie M., Waddick K.G., White J., Evans W.E. In vitro, in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 1995; 85: 2817 – 28
51. Uckun F.M., Chelstrom L.M., Finnegan D., Tuel Ahlgren L., Manivel C., Irvin J.D., Myers D.E., Gunther R. Effective immunochemotherapy of CALLA+C mu-+-human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116 – 29